Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RAD54 siRNA
- Development stage
- Unknown
- Lead developer
- Thermo Fisher Scientific
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral
01
Overview
RAD54 siRNA is a sequence-specific double-stranded RNA molecule designed to silence the expression of the RAD54 gene (typically the RAD54L isoform) via the RNA interference (RNAi) pathway. RAD54 is a member of the SWI2/SNF2 superfamily and plays a critical role in homologous recombination (HR) by promoting DNA strand exchange and stabilizing the RAD51-DNA nucleoprotein filament. By depleting RAD54, cells become deficient in repairing DNA double-strand breaks, which can sensitize them to DNA-damaging agents such as ionizing radiation or chemotherapy, and may induce synthetic lethality in certain genetic backgrounds. While primarily utilized as a research tool to investigate DNA repair mechanisms and potential therapeutic targets in oncology, it represents a class of RNA-based therapeutics aimed at modulating DNA damage response (DDR) pathways.
- Other names
- RAD54L siRNARAD-54L siRNARAD 54L siRNARAD54 small interfering RNARAD-54 small interfering RNARAD 54 small interfering RNA
02
Targets
DDR (DNA damage response)
Beyond the preview
Go deeper on RAD54 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RAD54 siRNA.